Toggle Main Menu Toggle Search

Open Access padlockePrints

Screening and purification of natural products from actinomycetes that affect the cell shape of fission yeast

Lookup NU author(s): Dr Richard Lewis, Nicholas Allenby, Professor Jeff ErringtonORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© 2017. This study was designed to identify bioactive compounds that alter the cellular shape of the fission yeast Schizosaccharomyces pombe by affecting functions involved in the cell cycle or cell morphogenesis. We used a multidrug-sensitive fission yeast strain, SAK950 to screen a library of 657 actinomycete bacteria and identified 242 strains that induced eight different major shape phenotypes in S. pombe. These include the typical cell cycle-related phenotype of elongated cells, and the cell morphology-related phenotype of rounded cells. As a proof of principle, we purified four of these activities, one of which is a novel compound and three that are previously known compounds, leptomycin B, streptonigrin and cycloheximide. In this study, we have also shown novel effects for two of these compounds, leptomycin B and cycloheximide. The identification of these four compounds and the explanation of the S. pombe phenotypes in terms of their known, or predicted bioactivities, confirm the effectiveness of this approach.


Publication metadata

Author(s): Lewis RA, Li J, Allenby NEE, Errington J, Hayles J, Nurse P

Publication type: Article

Publication status: Published

Journal: Journal of Cell Science

Year: 2017

Volume: 130

Issue: 18

Pages: 3173-3185

Print publication date: 15/09/2017

Online publication date: 03/08/2017

Acceptance date: 21/07/2017

Date deposited: 16/10/2017

ISSN (print): 0021-9533

ISSN (electronic): 1477-9137

Publisher: Company of Biologists Ltd

URL: https://doi.org/10.1242/jcs.194571

DOI: 10.1242/jcs.194571


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
093917
Cancer Research UK
FC001121
MRC
Wellcome Trust

Share